Skip to content

Clinical Trials for Chronic Urticaria

To Explore the Clinical Efficacy and Mechanism of optimized 'xiao-feng-san'

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100043671
Enrollment
Unknown
Registered
2021-02-26
Start date
2021-03-01
Completion date
Unknown
Last updated
2021-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic urticaria

Interventions

control group :to give “liang-xue-xiao-feng-san”decoction

Sponsors

Guang'anmen Hospital, China Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 48 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged 20 to 48 years; 2. patients conforming to the diagnostic criteria of refractory chronic urticaria; 3. patients conforming to the diagnostic criteria of TCM wind-heat syndrome; 4. patients having used at least 2 times the conventional dose of antihistamines or at least 2 combined antihistamines with conventional dose for more than 2 weeks; 5. The duration of patients'hives is more than 2 hours; 6. patients able to give stool samples; 7. patients able to sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients dignosed drug-induced urticaria, induced urticaria (cold urticaria, febrile urticaria, cholinergic urticaria), urticaria vasculitis and other skin diseases with urticaria-like manifestations; 2. patients who have been treated well with antihistamines or have been treated with hormones, immunosuppressants, or biological agents, or have received relevant Chinese medicine treatment 1 week before enrollment,or Patients who have received antibiotics and non-steroidal anti-inflammatory drugs 2 weeks before enrollment; 3. patients who are pregnant, or preparing for pregnant, or breastfeeding women; 4. patients suffering serious organic diseases of important organs such as heart, brain, liver and kidney,and those with severe primary diseases of the hematopoietic system, and those with mental illness; 5. patients allergic to the components of Chinese medicine in the research prescription.

Design outcomes

Primary

MeasureTime frame
urticaria activity score;Itch Severity Score;Hive Severity Score;time for hives subsidence;

Secondary

MeasureTime frame
Dermatology Life Quality Index;Sleep disturbance score;Activity Impact Score;

Countries

China

Contacts

Public ContactZhao Juan

Guang'anmen Hospital, China Academy of Chinese Medical Sciences

Zhaoj_0912@163.com+86 18701560058

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026